194 related articles for article (PubMed ID: 37047086)
1. Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis.
Andersen CSB; Kvist-Hansen A; Siewertsen M; Enevold C; Hansen PR; Kaur-Knudsen D; Zachariae C; Nielsen CH; Loft N; Skov L
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047086
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics.
Asahina A; Kubo N; Umezawa Y; Honda H; Yanaba K; Nakagawa H
J Dermatol; 2017 Oct; 44(10):1112-1121. PubMed ID: 28493493
[TBL] [Abstract][Full Text] [Related]
3. Association of Transition of Laboratory Markers with Transition of Disease Activity in Psoriasis Patients Treated with Biologics.
Annen S; Horiguchi G; Teramukai S; Ichiyama S; Ito M; Hoashi T; Kanda N; Saeki H
J Nippon Med Sch; 2022; 89(6):587-593. PubMed ID: 36725002
[TBL] [Abstract][Full Text] [Related]
4. Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer.
Hou Y; Li X; Yang Y; Shi H; Wang S; Gao M
Front Immunol; 2023; 14():1274431. PubMed ID: 38022654
[TBL] [Abstract][Full Text] [Related]
5. A study of the efficacy and safety of plaque psoriasis treatment by TNF-α and IL-17A inhibitor biologics in patients who received the inactivated SARS-CoV-2 vaccine.
Ye S; Sun H; Xu Z; Xu B; Wu N; Wu J
Immun Inflamm Dis; 2023 Jul; 11(7):e938. PubMed ID: 37506146
[TBL] [Abstract][Full Text] [Related]
6. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients.
Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J
Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748
[TBL] [Abstract][Full Text] [Related]
7. Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year.
Liu Y; Hu K; Jian L; Duan Y; Zhang M; Kuang Y
J Dermatolog Treat; 2024 Dec; 35(1):2331782. PubMed ID: 38513258
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Psoriasis Area and Severity Index as a Proxy for Bio-markers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles.
Hoffmann JHO; Knoop C; Schäkel K; Enk AH; Hadaschik EN
Acta Derm Venereol; 2021 May; 101(5):adv00462. PubMed ID: 33903917
[TBL] [Abstract][Full Text] [Related]
9. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.
Włodarczyk M; Sobolewska A; Wójcik B; Loga K; Fichna J; Wiśniewska-Jarosińska M
World J Gastroenterol; 2014 Jun; 20(22):7019-26. PubMed ID: 24944497
[TBL] [Abstract][Full Text] [Related]
10. Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis.
Shimauchi T; Hirakawa S; Suzuki T; Yasuma A; Majima Y; Tatsuno K; Yagi H; Ito T; Tokura Y
J Dermatol; 2013 Oct; 40(10):805-12. PubMed ID: 23915382
[TBL] [Abstract][Full Text] [Related]
11. Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis.
Muramatsu S; Kubo R; Nishida E; Morita A
Mod Rheumatol; 2017 Jan; 27(1):137-141. PubMed ID: 27194220
[TBL] [Abstract][Full Text] [Related]
12. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
[TBL] [Abstract][Full Text] [Related]
13. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.
Fitz L; Zhang W; Soderstrom C; Fraser S; Lee J; Quazi A; Wolk R; Mebus CA; Valdez H; Berstein G
Clin Exp Dermatol; 2018 Oct; 43(7):790-797. PubMed ID: 29748971
[TBL] [Abstract][Full Text] [Related]
14. Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling.
Johnston A; Guzman AM; Swindell WR; Wang F; Kang S; Gudjonsson JE
Br J Dermatol; 2014 Jul; 171(1):97-107. PubMed ID: 24601997
[TBL] [Abstract][Full Text] [Related]
15. High Levels of Platelet-Lymphocyte Complexes in Patients with Psoriasis Are Associated with a Better Response to Anti-TNF-α Therapy.
Sanz-Martínez MT; Moga E; Sánchez Martínez MA; Zamora Atenza C; Vidal S; Juárez C; Puig L
J Invest Dermatol; 2020 Jun; 140(6):1176-1183. PubMed ID: 31778714
[TBL] [Abstract][Full Text] [Related]
16. IL-1β, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients.
Zhang B; Jiang W
Inflammopharmacology; 2019 Dec; 27(6):1123-1130. PubMed ID: 31463666
[TBL] [Abstract][Full Text] [Related]
17. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version).
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Sano S; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 Feb; 50(2):e41-e68. PubMed ID: 36582113
[TBL] [Abstract][Full Text] [Related]
18. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ.
Curmin R; Guillo S; De Rycke Y; Bachelez H; Beylot-Barry M; Beneton N; Chosidow O; Dupuy A; Joly P; Jullien D; Richard MA; Viguier M; Sbidian E; Paul C; Mahé E; Tubach F;
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2101-2112. PubMed ID: 35793473
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis.
Green LJ; Yamauchi PS; Kircik LH
J Drugs Dermatol; 2019 Aug; 18(8):776-788. PubMed ID: 31424708
[TBL] [Abstract][Full Text] [Related]
20. Serum high-sensitivity C-reactive protein, tumor necrosis factor-α, interleukin (IL)-1β, IL-17A and IL-23 levels in patients with hidradenitis suppurativa.
Saraç Öztürk G; Ergun T; Peker Eyüboğlu İ; Akkiprik M
Cytokine; 2021 Aug; 144():155585. PubMed ID: 34034145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
